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Background: Glomerular filtration rate (GFR)-estimating equations are used to determine 
the prevalence of chronic kidney disease (CKD) in population-based studies. However, it has 
been suggested that since the commonly used GFR equations were originally developed from 
samples of patients with CKD, they underestimate GFR in healthy populations. Few studies have 
made side-by-side comparisons of the effect of various estimating equations on the prevalence 
estimates of CKD in a general population sample.
Patients and methods: We examined a population-based sample comprising adults from 
Wisconsin (age, 43–86 years; 56% women). We compared the prevalence of CKD, defined as a 
GFR of ,60 mL/min per 1.73 m2 estimated from serum creatinine, by applying various com-
monly used equations including the modification of diet in renal disease (MDRD) equation, 
Cockcroft–Gault (CG) equation, and the Mayo equation. We compared the performance of these 
equations against the CKD definition of cystatin C .1.23 mg/L.
Results: We found that the prevalence of CKD varied widely among different GFR equations. 
Although the prevalence of CKD was 17.2% with the MDRD equation and 16.5% with the CG 
equation, it was only 4.8% with the Mayo equation. Only 24% of those identified to have GFR in 
the range of 50–59 mL/min per 1.73 m2 by the MDRD equation had cystatin C levels .1.23 mg/L; 
their mean cystatin C level was only 1 mg/L (interquartile range, 0.9–1.2 mg/L). This finding 
was similar for the CG equation. For the Mayo equation, 62.8% of those patients with GFR in 
the range of 50–59 mL/min per 1.73 m2 had cystatin C levels .1.23 mg/L; their mean cystatin 
C level was 1.3 mg/L (interquartile range, 1.2–1.5 mg/L). The MDRD and CG equations showed 
a false-positive rate of .10%.
Discussion: We found that the MDRD and CG equations, the current standard to estimate GFR, 
appeared to overestimate the prevalence of CKD in a general population sample.
Keywords: chronic kidney disease, glomerular filtration rate, MDRD equation, Cockcroft–Gault 
equation, Mayo equation
Introduction
Glomerular filtration rate (GFR) is an important indicator of kidney function.1 
However, in practice, since GFR is usually not directly measured for routine 
clinical or research purposes, markers, such as serum creatinine, are used to esti-
mate GFR. Estimating equations, such as the modification of diet in renal disease 
(MDRD) study equation2 or the Cockcroft–Gault (CG) equation,3 are widely 
used for this purpose. However, the MDRD or the CG equations were developed 
from chronic kidney disease (CKD) populations and not from general population 
samples.2,3 Though several studies have successfully applied the MDRD equation, 
Rule et al4 showed that although the MDRD equation was reasonably accurate Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in estimating GFR in patients with CKD, it significantly 
underestimated measured GFR in healthy persons in their 
cohort. Several other studies in general populations have 
also reported similar issues with the MDRD equation.5–11 
It was postulated that the use of an equation developed 
for CKD patients with decreased GFR would potentially 
underestimate GFR in a healthy population.12 An alterna-
tive Mayo clinic quadratic GFR-estimating equation was 
developed, using measured GFR from healthy kidney 
donors in addition to CKD patients, to provide an equation 
with higher degree of generalizability.4
The purpose of this report is to describe approaches for 
using GFR-estimating equations in a general population 
sample in which we use traditional and alternative cutoffs 
to define CKD, to describe the strategies adopted in the 
absence of a direct measure of GFR, and to examine the 
accuracy of each cutoff. Hence, we analyzed the data from 
a population-based study of predominantly white subjects 
aged 43–86 years from Wisconsin to study the incidence of 
CKD and its related risk factors.
Patients and methods
The methods used to identify and describe the population have 
appeared in previous reports.13–15 In brief, a private census of 
the population of Beaver Dam, Wisconsin, was performed 
from September 1987 to May 1988 to identify all residents in 
the city or township of Beaver Dam who were 43–84 years of 
age. Of the 5,924 eligible individuals (98% Caucasians), 4,926 
(83.1%) participated in the baseline examination between 
March 1, 1988, and September 14, 1990. Comparisons between 
participants and nonparticipants at the time of the baseline 
examination have appeared elsewhere.13 Written informed 
consent was obtained from each subject. This study followed 
the recommendations of Declaration of Helsinki and was 
approved by the Human Subjects Committee of the University 
of Wisconsin Medical School, Madison.
Of 4,926 individuals who participated in the baseline 
examination, there were 4,898 individuals with serum creati-
nine measurements and complete covariate information from 
the study population for the cross-sectional analysis.
The study included the following examinations: (1) mea-
suring weight, height, systolic and diastolic blood pressure by a 
trained observer; (2) administering standardized questionnaire 
that collected information regarding participants’ demographic 
characteristics and details regarding cigarette smoking, alcohol 
intake, medical histories, and medications taken, including 
diagnosis of diabetes or hypertension by a physician.
Casual blood specimens were obtained for the 
measurement of plasma glucose and serum creatinine 
levels. Plasma and serum were stored without preservative 
at −80°C in cryogenic vials with O-rings for up to 17 years, 
until the vials were shipped on dry ice to the University of 
Minnesota laboratory for the analyses. Serum creatinine 
was measured by an enzymatic method (CREA plus®; 
Roche Diagnostics, Indianapolis, IN, USA) using the Roche 
Modular P Chemistry Analyzer (Roche Diagnostics), con-
sistent with the current National Kidney Disease Education 
Program (NKEDP) recommendations for standardizing 
serum creatinine measurement.16 The laboratory coefficient 
of variability (CV) was 1.96% at a level of 0.76 mg/dL and 
2.2% at a level of 3.6 mg/dL. Serum cystatin C was deter-
mined by nephelometry technique using the Dade Behring 
BN100 nephelometer (Deerfield, IL, USA). The interassay 
precision was determined at 2 control levels: 1.72 mg/L 
(CV 6.4%) and 0.78 mg/L (CV 5.2%).
Age was defined as the participants’ age at the time of 
baseline examination. Education was categorized as below 
high school, and high school and above. Body mass index 
(BMI) was defined as participants’ weight in kilograms 
divided by the height in meters squared. Hypertension 
was defined as a systolic blood pressure of 140 mm Hg 
or higher, a diastolic blood pressure of 90 mm Hg or 
higher, or the combination of self-reported hypertension 
diagnosis by a physician and the use of antihypertensive 
medications. Persons were defined as having diabetes 
mellitus if they had high blood glucose or a history of 
diabetes diagnosis by a physician, or if they are treated 
with insulin, oral hypoglycemic agents, or diet. High blood 
glucose is defined as the presence of a casual blood glucose 
value .200 mg/dL (11.1 mmol/L) or elevated glycosylated 
hemoglobin value .2 standard deviations above the mean 
for a given age–gender group.17
The reexpressed MDRD equation was used to estimate 
GFR from serum creatinine.2 Estimated GFR (eGFR) was 
also calculated using the CG equation3 indexed for body 
surface area, the cystatin C equation18 incorporating age, 
sex, and race, the Mayo equation,4 and the combined serum 
creatinine and cystatin C equation.18 CKD was primarily 
defined as eGFR , 60 mL/min per 1.73 m2 consistent 
with stage 3, 4, or 5 CKD. We also used the following 
secondary definitions of CKD: eGFR , 45 mL/min per 
1.73 m2, cystatin C level .1.23 mg/L (corresponding 
to an eGFR , 60 mL/min per 1.73 m2),18,19  and 
cystatin C .99th percentile (corresponding to cystatin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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C level .1.67 mg/L) among subjects without diabetes 
mellitus and hypertension.
Statistical methods
First, we described the baseline characteristics of the 
population. Second, we examined the distribution of eGFR 
categories (,40 mL/min per 1.73 m2, 40–49 mL/min per 
1.73 m2, 50–59 mL/min per 1.73 m2, 60–69 mL/min per 
1.73 m2, 70–79, and $80 mL/min per 1.73 m2) calculated 
by each GFR-estimating equation. We then analyzed the 
distribution of cystatin C levels and also compared the 
prevalence of cystatin C level .1.23 mg/L (correspond-
ing to an eGFR , 60 mL/min per 1.73 m2)18,19 obtained 
by eGFR categories according to the various estimating 
equations. We chose this direct cystatin C cutoff as the 
standard to compare, instead of using the cystatin C-based 
GFR-estimating equations from the CKD-Epidemiology 
Study18 because these estimating equations were also origi-
nally derived from CKD samples, and we suspected, based 
on the distribution of their eGFR categories in a preliminary 
analysis, that it could have similar underestimation of GFR 
as the creatinine-based equations.
Third, we compared the performance of the CKD defi-
nition of eGFR , 60 mL/min per 1.73 m2 from the serum 
creatinine-based GFR-estimating equations (MDRD, CG, and 
Mayo equations) with that of the CKD definition of cystatin C 
level .1.23 mg/L. We calculated sensitivity, specificity, posi-
tive predictive value, negative predictive value, 1-sensitivity, 
and 1-specificity as the quantitative measures of validity.20 We 
also examined whether the following alternative strategies 
would perform better: (1) by using a lower eGFR cutoff of 
45 mL/min per 1.73 m2 or (2) by combining CKD definitions 
from more than 1 serum creatinine-based estimating equa-
tion. We examined an ad hoc definition of CKD as MDRD 
equation eGFR , 45 mL/min per 1.73 m2 or Mayo equation 
eGFR , 60 mL/min per 1.73 m2.
Finally, despite following the laboratory calibration trace-
able to criterion standard reference methods in measuring 
serum creatinine,16 we examined in a Bland–Altman 
plot, whether residual differences in laboratory measure-
ments between our laboratory (Fairview laboratory) and 
the Cleveland Clinical Laboratory were the basis for the 
observed underestimation of eGFR from MDRD equation. 
In this interlaboratory reliability substudy, we performed 
paired measurements of serum creatinine from the Fairview 
laboratory and the Cleveland Clinical Laboratory on 
134 subjects from the current study sample.
We also performed the following supplementary 
analyses. We examined selected factors, including age, 
gender, smoking, alcohol intake, BMI, diabetes mellitus, 
and hypertension and their association with CKD defined as 
cystatin C level .1.23 mg/L by using multivariable logistic 
regression models; we calculated the odds ratio (OR) and 
95% confidence interval (CI) of CKD associated with each 
factor. We also replicated the entire analysis using an alter-
nate cystatin C cutoff, defined as cystatin C .99th percentile 
among subjects without diabetes mellitus and hypertension, 
as the standard to compare. All analyses were performed 
in Statistical Analysis System (version 9.1; SAS, Institute, 
Cory, NC).
Results
Table 1 describes the baseline characteristics of the study 
population. In brief, slightly more than half of the subjects 
were women, approximately 70% had high school and above 
education, and about one-fifth of them were current smokers. 
The mean serum creatinine level was 0.9 mg/dL and mean 
serum cystatin C was 0.9 mg/L. In the same population, the 
mean eGFR varied according to the estimating equation used; it 
was the lowest for MDRD equation with a mean MDRD eGFR 
of 76.2 mL/min per 1.73 m2 and the highest for Mayo equation 
with mean Mayo eGFR of 93.5 mL/min per 1.73 m2.
Table 2 presents the distribution of eGFR categories 
according to the various estimating equations. The prevalence 
of CKD defined as eGFR , 60 mL/min per 1.73 m2 was 17.2% 
with the MDRD equation, 16.5% with the CG equation, 4.8% 
with the Mayo equation, 14.1% with the cystatin C equation 
that included terms for age and gender, 12.1% with the equation 
that included cystatin C, serum creatinine, age, and gender, and 
9.5% when using a definition of cystatin C . 1.23 mg/L.
Table 2 also shows the distribution of cystatin C levels 
by eGFR categories according to the various estimating 
equations. For this comparison, we used criteria from 
earlier reports19,21 that showed that serum cystatin 
C level of 1 mg/L corresponds to a GFR of approximately 
80 mL/min per 1.73 m2 and cystatin C level of 1.23 mg/L 
corresponds to a GFR of approximately 60 mL/min per 
1.73 m2. We found that there is an apparent underestimation 
of the GFR when comparing the MDRD and CG equations 
with the eGFR categories and cystatin C levels side by side. 
For example, the mean cystatin C level was only 1 mg/L 
(interquartile range, 0.9–1.2 mg/L) among those identi-
fied to be having eGFR in the range of 50–59 mL/min per 
1.73 m2 by the MDRD equation. Similarly, the mean serum Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
622
Shankar et al
cystatin C level was only 1.1 mg/L (interquartile range, 
0.9–1.2) among those identified to be having eGFR in the 
range of 50–59 mL/min per 1.73 m2 by the CG equation. 
However, with the Mayo equation, the mean cystatin C 
level among those identified to be having eGFR in the range 
of 50–59 mL/min per 1.73 m2 was 1.3 mg/L (interquartile 
range, 1.2–1.5 mg/L).
We also compared the prevalence of cystatin C . 1.23 mg/L 
by eGFR categories according to various estimating equations 
(Table 2). Only 24% of those identified to be having eGFR 
in the range of 50–59 mL/min per 1.73 m2 by the MDRD 
equation had a cystatin C level .1.23 mg/L; for the CG equa-
tion this finding was similar (23.7%). For the Mayo equation, 
62.8% of those with eGFR in the range of 50–59 mL/min 
per 1.73 m2 had cystatin C levels .1.23 mg/L.
In the current study, we were interested in defining CKD 
based on a serum creatinine-based eGFR cutoff because 
only serum creatinine levels were available from all study 
participants at both the baseline and subsequent follow-up 
examinations. In Table 3, we, therefore, compared the 
performance of a CKD definition of eGFR ,60 mL/min 
per 1.73 m2 from serum creatinine-based GFR-estimating 
equations with that of a CKD definition of cystatin 
C level .1.23 mg/L. We also examined whether the fol-
lowing alternative strategies would perform better: (1) by 
using a lower eGFR cutoff of 45 mL/min per 1.73 m2 or (2) 
by combining CKD definitions from more than one serum 
creatinine-based estimating equations. In general, an eGFR 
cutoff of ,60 mL/min per 1.73 m2 based on the MDRD 
and CG equations had moderate sensitivity and specificity. 
However, both these equations showed a false-positive rate 
of .10%. An eGFR cutoff of ,60 mL/min per 1.73 m2 
based on the Mayo equation appeared to have adequate 
specificity (98.8%) and low false-positive rate (1.2%) but 
a low sensitivity (38%). When we used an eGFR cutoff 
of ,45 mL/min per 1.73 m2 to define CKD, the false-positive 
rate of MDRD equation dramatically improved to 1.2%. 
Finally, we examined an ad hoc definition of CKD as MDRD 
equation eGFR of ,45 mL/min per 1.73 m2 or Mayo equation 
eGFR of ,60 mL/min per 1.73 m2. The ad hoc definition 
appeared to function similar to the Mayo equation eGFR 
cutoff of ,60 mL/min per 1.73 m2.
In a Bland–Altman plot (Figure 1) on 134 subjects with 
paired measurements of serum creatinine from the Fairview 
laboratory and the Cleveland Clinical Laboratory, we 
found that all but nine subjects had the difference in serum 
creatinine between these two laboratory measurements within 
±2 standard deviations.
In  a  supplementary  analysis,  we  examined  the 
association between selected factors and CKD, defined as a 
cystatin C level .1.23 mg/L. The OR (95% CI) for CKD was 
1.14 (1.12–1.16) for age (per year), 1.08 (0.85–1.37) for gender 
(men vs women), 0.99 (0.78–1.24) for education (below high 
school vs high school and above), 1.78 (1.28–2.48) for smoking 
(current vs former/never), 1.00 (0.99–1.01) for alcohol intake 
(grams/week), 1.07 (1.05–1.09) for BMI (per kg/m2), 1.25 
(0.95–1.64) for diabetes mellitus, and 2.00 (1.55–2.57) for 
hypertension. In the second supplementary analysis, when we 
repeated the analysis in Table 3 using cystatin C .99th percentile 
among subjects without diabetes mellitus and hypertension as 
the standard to compare, the results were found to be essentially 
the same.
Discussion
In a population-based cohort of white middle-aged to older 
adults from Wisconsin, we found that the MDRD and CG 
equations, the current standard to estimate GFR, appeared 
to overestimate the prevalence of CKD. When we compared 
serum cystatin C levels side by side with eGFR categories 
from these equations, it appeared that this was related to 
an underlying underestimation of eGFR. In this general 
population sample, these current standard GFR-estimating 
equations also had high false-positive rates of more than 10% 
when compared with a cystatin C approach in identifying 
kidney disease. Our findings add to the existing literature 
Table 1  Baseline characteristics of the study population
Characteristics Mean (standard deviation) or %
Age, y 62.0 (11.2)
Women, % 55.9%
education, %
  Below high school 29.2%
  High school and above 70.8%
Smoking, %
  never/former smoker 80.3%
  current smoker 19.7%
Alcohol intake, g/wk 54.8 (121.3)
Body mass index kg/m2 28.8 (5.4)
Body surface area, m2 1.82 (0.2)
Diabetes mellitus, % 9.1%
Hypertension, % 50.3%
Serum creatinine, mg/dL 0.9 (0.3)
Serum cystatin c, mg/L 0.9 (0.3)
Mean MDRD egFRa‡ 76.2 (18.7)
Mean cockcroft–gault egFRa 82.9 (24.0)
Mean Mayo equation egFRa 93.5 (17.8)
Mean cystatin c equation egFRa 84.3 (23.6)
Mean combined cystatin c and 
creatinine equation egFRa
83.1 (20.1)
Note: aEstimated glomerular filtration rate, mL/min per 1.73 m2.
Abbreviation: MDRD, modification of diet in renal disease.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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that has reported similar unexpected findings with the MDRD 
equation when applied to general population samples.4–11
Published estimates from the third National Health 
and Nutrition Examination Survey (NHANES) (compa-
rable to our baseline examination period) reported the 
prevalence of eGFR ,60 mL/min per 1.73 m2 to be 4.5%.22 
In the recent NHANES 1999–2004, the prevalence of 
eGFR , 60 mL/min per 1.73 m2 was found to be 8.1%.23 In 
the current study, we found that the prevalence estimates of 
CKD varied widely between the different GFR-estimating 
Table 2 Distribution of egFR and cystatin c according to various estimating equations
eGFR category  
(mL/min per 1.73 m2)
Cystatin C distribution (mg/L)
Number % Mean Standard  
deviation
Lower  
quartile
Median Upper  
quartile
No. (%) with   
cystatin C  
.1.23 mg/L
MDRD equation
  ,40 121 2.6% 1.9 0.7 1.5 1.8 2.3 107 (88.4%)
  40–49 229 4.9% 1.3 0.3 1.1 1.3 1.5 125 (54.6%)
  50–59 447 9.7% 1.0 0.3 0.9 1.1 1.2 108 (24.2%)
  60–69 836 18.1% 0.9 0.2 0.8 0.9 1.1 65 (7.8%)
  70–79 1112 24.0% 0.9 0.2 0.8 0.9 1.0 26 (2.3%)
  $80 1883 40.7% 0.8 0.1 0.7 0.8 0.9 13 (0.7%)
cockcroft–gault equation
  ,40 142 3.1% 1.8 0.7 1.4 1.7 2.1 120 (84.5%)
  40–49 196 4.2% 1.3 0.3 1.1 1.2 1.5 99 (50.5%)
  50–59 427 9.2% 1.1 0.3 0.9 1.1 1.2 101 (23.7%)
  60–69 627 13.5% 1.0 0.2 0.9 1.0 1.1 70 (11.2%)
  70–79 738 15.9% 0.9 0.2 0.8 0.9 1.0 29 (3.9%)
  $80 2498 54.0% 0.8 0.1 0.7 0.8 0.9 25 (1.0%)
Mayo equation
  ,40 64 1.4% 2.3 0.8 1.8 2.1 2.5 61 (95.3%)
  40–49 56 1.2% 1.6 0.4 1.4 1.6 1.8 45 (80.4%)
  50–59 102 2.2% 1.3 0.3 1.2 1.3 1.5 64 (62.8%)
  60–69 193 4.2% 1.3 0.3 1.1 1.2 1.4 93 (48.2%)
  70–79 322 7.0% 1.1 0.3 0.9 1.1 1.2 76 (23.6%)
  $80 3891 84.0% 0.9 0.2 0.7 0.8 1.0 105 (2.7%)
cystatin c equationa
  ,40 145 3.1% 2.1 0.6 1.7 1.9 2.2 145 (100%)
  40–49 188 4.1% 1.4 0.09 1.3 1.4 1.5 188 (100%)
  50–59 320 6.9% 1.2 0.07 1.1 1.2 1.3 111 (4.7%)
  60–69 553 11.9% 1.1 0.06 1.0 1.0 1.1 0 (0%)
  70–79 738 15.9% 1.0 0.05 0.9 0.9 1.0 0 (0%)
  $80 2684 58.0% 0.8 0.09 0.7 0.8 0.8 0 (0%)
combined cystatin c  
and creatinine equationa
  ,40 114 2.5% 2.2 0.6 1.8 2.0 2.4 114 (100%)
  40–49 164 3.5% 1.4 0.2 1.3 1.5 1.6 143 (87.2%)
  50–59 284 6.1% 1.2 0.1 1.1 1.2 1.3 134 (47.2%)
  60–69 545 11.8% 1.1 0.1 1.0 1.1 1.1 46 (8.4%)
  70–79 805 17.4% 0.9 0.1 0.9 1.0 1.1 6 (0.8%)
  $80 2716 58.7% 0.8 0.1 0.7 0.8 0.9 1 (0.04%)
Note: aequations 2 and 3 in Table 4 of Stevens et al.18
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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equations. While the prevalence rate of CKD defined as 
eGFR ,60 mL/min per 1.73 m2 was 17.2% with the MDRD 
equation and 16.5% with the CG equation, it was only 4.8% 
with the Mayo equation. Also, when we defined CKD as 
cystatin C level .1.23 mg/L, the prevalence of CKD was 
9.5%. The substantial differences in the prevalence of CKD 
by different GFR-estimating equations suggest that selection 
bias in their original study samples may limit their generaliz-
ability. In particular, the high prevalence estimates came from 
equations that were originally derived from CKD populations, 
whereas the low prevalence estimates came from the Mayo 
study, which included kidney donors, a group who may be 
considered to be “super healthy”4 compared with general 
population samples.
When the MDRD equation was initially published 
in 1999,24 it was shown that a direct application of the 
MDRD equation without calibration to the Cleveland 
Clinical Laboratory, where the MDRD serum creatinine 
levels were measured, would provide biased estimates of 
GFR.25 In a calibration substudy involving NHANES III 
samples, Coresh et al25 noted that the bias in estimating 
GFR was only approximately 8% at a GFR of 25 mL/min 
per 1.73 m2 but was more than 25% at a higher GFR of 
100 mL/min per 1.73 m2. It is possible that in addition 
to calibration issues between laboratories, this pattern of 
lower difference in GFR estimation among subjects with 
kidney disease compared with larger differences among 
healthy subjects is partly due to a GFR underestimation 
bias with the MDRD equation when applied to general 
population samples.
In this context, Rule et al4 showed that in spite of cali-
bration, the MDRD equation could be applied accurately in 
patients with CKD, whereas it substantially underestimated 
GFR in healthy persons. In the Framingham Heart Study, Fox 
et al6 noted that even after calibration, the use of an MDRD 
eGFR cutoff of ,60 mL/min per 1.73 m2 overestimated CKD 
in women; a different ad hoc cutoff defined as eGFR at or 
below the sex-specific fifth percentile was used to define CKD 
in that study. Several other studies in non-CKD populations 
have also reported similar issues with the MDRD equation.7–10 
Table 3  Accuracy of various eGFR cutoffs to define kidney disease
eGFR 
(mL/min per 1.73 m2)
Kidney disease defined as cystatin C .1.23 mg/L
No. of  
cases/No. 
at risk
Prevalence Sensitivity Specificity Positive  
predictive 
value
Negative  
predictive 
value
False  
positive rate
False  
negative 
rate
MDRD equation
  $60 104/3831 2.7%
  ,60 340/797 42.7% 76.6% 89.1% 42.7% 97.3% 10.9% 23.4%
  $45 287/4134 6.5%
  ,45 157/207 75.8% 35.4% 98.8% 75.8% 93.5% 1.2% 64.6%
cockcroft–gault  
equation
  $60 124/3863 3.2%
  ,60 320/765 6.9% 72.1% 89.4% 41.8% 96.8% 10.6% 27.9%
  $45 272/4403 6.2%
  ,45 172/225 76.4% 38.7% 98.7% 76.4% 93.8% 1.3% 61.3%
Mayo equation
  $60 274/4406 6.2%
  ,60 170/222 76.6% 38.3% 98.8% 76.6% 93.8% 1.2% 61.7%
  $45 364/4540 8.0%
  ,45 80/88 90.9% 18.0% 99.8% 90.9% 92.0% 0.2% 82.0%
Ad hoc cKD  
definitiona
  Absent 266/4382 6.1%
  Present 178/246 72.3% 40.1% 98.4% 72.4% 93.9% 1.6% 59.9%
Note: aCKD defined in the current study as either MDRD equation eGFR ,45 mL/min per 1.73 m2 or Mayo equation egFR ,60 mL/min per 1.73 m2.
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; CKD, chronic kidney disease.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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It has been hypothesized that as regression analysis, a 
statistical technique which fits data to the observed mean, 
was used in developing these GFR-estimating equations, the 
accuracy of the GFR estimates would be lower in populations 
with different ranges of GFR than in the MDRD sample popu-
lation.12 It is, therefore, possible that the use of an equation 
developed for CKD patients with decreased GFR would in 
turn underestimate GFR in a healthy population.12
In NHANES III, when Clase et al5 applied the MDRD 
equation and found an unexpected high prevalence of CKD 
among nondiabetic US adults, it was believed to be entirely 
explained by the lack of calibration of serum creatinine 
values.26 Since the publication of the reexpressed MDRD 
equation2 and the use of standardized serum creatinine assay 
measurements in the latest NHANES survey, calibration 
may be less of an issue in the current NHANES prevalence 
estimates.
Therefore, the recent findings of a substantially higher national 
estimate of low eGFR in the NHANES 1999–2004 that could not 
be fully explained by risk factors, such as an aging US popula-
tion and an increased prevalence of diabetes, hypertension, and 
obesity,23 are consistent with our hypothesis that the MDRD 
equation perhaps may be underestimating eGFR when applied 
to a general population sample. In contrast to the findings for low 
eGFR, the higher prevalence rate of albuminuria observed in the 
NHANES 1999–2004 was almost entirely explained by adjustment 
for risk factors, such as age, diabetes, hypertension, and obesity.23 
This further strengthens our hypothesis, as for a true increase in 
CKD one would expect comparable increases in both albuminuria 
and low eGFR. We believe that further studies are needed in the 
generalizability of MDRD equation to non-CKD populations.
Brenner and Savitz27 demonstrated that in epidemiological 
studies examining associations between specific risk factors and 
a relatively rare outcome, specificity of case diagnosis should 
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take precedence over sensitivity for the sake of study validity. 
They showed that although increasing the specificity and sacri-
ficing sensitivity may compromise precision to some extent, the 
latter can often be fully compensated for by an increased sample 
size (or control: case ratio).27 However, an imperfect specificity 
compromises power, despite increased sample size.27 In this 
context, a corollary observation based on our findings is that in 
studies, such as ours examining risk factors for CKD, kidney 
disease definitions with higher specificity, such as an MDRD 
eGFR of , 45 mL/min per 1.73 m2, may be more desirable than 
the commonly used cutoff of MDRD eGFR of , 60 mL/min per 
1.73 m2–which has higher sensitivity but lower specificity.
The main advantages of our study include its population-
based nature and the availability of serum creatinine and cystatin 
C from all subjects for a side-by-side comparison. The main 
study limitation is the lack of a gold standard, a direct mea-
surement of GFR, to compare as a standard against the various 
GFR-estimating equations. This may have biased our estimates 
of sensitivity and specificity comparing CKD definition from 
various GFR-estimating equations. However, it should be noted 
that we did not expect to observe underestimation of GFR before 
the study and did not have the current results as an a priori 
hypothesis before data collection. In fact, the current study was 
originally aimed at studying risk factors of CKD, defined as 
MDRD eGFR ,60 mL/min per 1.73 m2. In the current analysis, 
we followed a pragmatic approach and chose a direct cystatin 
C cutoff as the standard because the underlying hypothesis of 
this article is that the application of GFR-estimating equations 
originally developed in CKD samples underestimates the true 
GFR value in a general population sample.
Another potential limitation is that in one of the analyses, 
we defined CKD as cystatin C .99th percentile among study 
subjects without diabetes or hypertension. However, all our study 
subjects were older than 45 years. Similar definitions in previous 
studies used a cutoff of cystatin C .99th percentile among those 
subjects without diabetes or hypertension and among young 
adults (ie, 20–39 years). Due to the age difference, our 99th 
percentile level is higher than similar cutoffs from young adults 
in previous studies. It is possible that some of the older adults in 
our study may be misclassified as being free of CKD.
In summary, in population-based sample of white middle-
aged adults from Wisconsin, we found that the MDRD and 
CG equations appeared to overestimate the prevalence of CKD 
and that this was related to an underestimation of eGFR. These 
current standard equations also had a high false-positive rate of 
more than 10% when compared with  a direct cystatin C cutoff 
in identifying kidney disease. Furthermore, these findings may 
also have potential clinical implications. As eGFR calculations 
are now appearing in reports from clinical laboratories, values 
of eGFR that are falsely positive would lead to a series of 
unnecessary tests. Our findings add to the existing literature4–11 
and support the argument that further research is required 
before we conclude regarding the generalizability of MDRD 
equation to non-CKD populations.
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